- ~900-1200 people diagnosed/yr in U.S.
- Mostly between 15-60 years old
- Slightly more common in women than men
- Often undergo multiple and costly surgical and pharmaceutical treatments with limited success
Daniel S. Lynch joined SpringWorks Therapeutics at launch in 2017 and is currently Executive Chairman. Since October 2007, Daniel has advised and served as executive chair or member of the board of directors for a number of private biopharmaceutical companies, including Stromedix, Inc. (until its acquisition by Biogen Idec in February 2012), Avila Therapeutics, Inc. (until its acquisition by Celgene Corporation in February 2012), RaNA Therapeutics, Inc., Nimbus Discovery, LLC, Edimer Pharmaceuticals, Ember Therapeutics, Inc. and Blueprint Medicines, Inc. He serves on the board of directors of BIND Biosciences, Inc. and Eleven Biotherapeutics, Inc. Previously, Daniel served as chief executive and chief financial officer of ImClone Systems Corporation, or ImClone. As ImClone’s chief executive officer, he led ImClone through a significant turnaround, helping to restore the company’s reputation and to secure FDA approval of ERBITUX (Cetuximab), a novel cancer treatment. As its chief financial officer, Daniel led negotiations to form the major partnership between ImClone and Bristol-Myers Squibb. Earlier in his career, he served in various financial positions at Bristol-Myers Squibb over a 15-year tenure. He served on the board of directors and the audit committee of U.S. Oncology, Inc. for five years until December 2010, when it was acquired by McKesson. Daniel received his B.A. in mathematics from Wesleyan University and his MBA from the Darden Graduate School of Business Administration at the University of Virginia.
Lara Sullivan brings to SpringWorks Therapeutics more than two decades of experience and senior leadership in biopharmaceuticals, healthcare and life sciences, most recently at Pfizer. While at Pfizer she helmed strategy and portfolio operations for the company’s early stage pipeline and led the work, inside Pfizer and with outside patient groups and partners, to create SpringWorks Therapeutics. Lara joined Pfizer from McKinsey & Company, where she was an associate partner in the pharmaceutical and medical products practice advising biopharmaceutical clients on a variety of strategic and operational issues, with a particular emphasis on R&D productivity. Additionally, Lara was a principal at Paul Capital Partners leading due diligence for investments in the healthcare fund, and earlier in her career worked in healthcare equity research and municipal finance at CS First Boston. Lara holds an M.D. from the University of Pennsylvania School of Medicine, an MBA from The Wharton School at the University of Pennsylvania, and a B.A. in comparative literature from Cornell University.
Saqib Islam joined SpringWorks Therapeutics from Moderna Therapeutic, where he served as chief business officer and oversaw critical aspects of the company’s growth, including global strategic planning, corporate development and business development. Saqib joined Moderna from Alexion Pharmaceuticals, where he served as executive vice president, chief strategy and portfolio officer, executing the company’s corporate growth strategies and contributing to its assessment and management of global operations. Prior to joining Alexion, Saqib worked for more than 25 years in international business management with a focus on business development, strategic decision-making and planning and capital markets. He has an extensive background in the healthcare banking sector, having held positions of increasing responsibility in the investment banking divisions of as a managing director at Morgan Stanley, and most recently, Credit Suisse Securities. Earlier in his career, Saqib provided strategic analysis and advice to client firms across diverse industry segments for The Boston Consulting Group. Saqib received a bachelor’s degree from McGill University, graduating as a University Scholar, and a J.D. from Columbia Law School, where he was a Harlan Fiske Stone Scholar.
Stephen Squinto, PH.D., joined SpringWorks Therapeutics at launch in 2017 and is acting Head of Research and Development. Steve is a Venture Partner with OrbiMed who brings over 25 years of biotechnology industry experience. Steve was a co-founder of Alexion Pharmaceuticals, Inc. and recently served as its Executive Vice President and Chief Global Operations Officer. Prior to 2013, he was Alexion's Global Head of Research and Development. From 1988 to 1992, Steve held various positions at Regeneron Pharmaceuticals, Inc. Prior to Regeneron, he held a joint academic position at both the Tulane University and LSU Medical Schools. He is a recipient of numerous honors and awards from academic and professional organizations for his scientific work. Steve received his B.A. in Chemistry and PH.D. in Biochemistry and Biophysics from Loyola University of Chicago.
Mary Smith joined SpringWorks Therapeutics at launch in 2017 to lead Clinical Research and Drug Development. She brings over 20 years of research and clinical development experience from both pharmaceutical- and biotechnology-focused companies. She has experience in all stages of drug development from target discovery through all phases of clinical development and commercial launch. Most recently, Mary was the executive director of gene therapy at Bamboo Therapeutics, a wholly owned subsidiary of Pfizer where she led several key gene transfer programs for rare genetic diseases. Prior to joining Bamboo, Mary spent 12 years at United Therapeutics as the vice president of product development. In that role, she was head of biologics development in oncology, with additional responsibility for regenerative medicine and virology. Specifically, she led the multi-disciplinary team responsible for the clinical development and approval of Unituxin®, the first approved immunotherapy for the treatment of high-risk neuroblastoma in the U.S. and EU. She also managed the regenerative medicine program, which included mesenchymal stem cell therapies and lung regeneration efforts. Mary earned a Ph.D. in microbiology/immunology from the University of New Hampshire followed by post-doctoral training at Emory University.
Paul Barclay joined SpringWorks Therapeutics at launch in 2017 and is responsible for project management of the SpringWorks Therapeutics portfolio, driving our drug development programs to deliver on time, within scope and on budget, to ensure we rapidly advance differentiated, medically valuable treatments to patients. Paul brings to our team a broad experience of drug development in a range of disease areas including cardiovascular, neurosciences, inflammation and oncology and across multiple therapeutic modalities (small molecules, biologics, MAbs, cell-based and gene therapies). Before joining SpringWorks, Paul served as the head of development management and planning in global product development at Pfizer, with oversight for asset project management and development strategy from lead development to clinical proof of concept. During his long tenure at Pfizer, he has held leadership positions as development strategy leader, early candidate medical director, development team leader and research team leader with a successful track record of leading programs from early discovery research through all phases of clinical development including registration and post-approval. Paul holds a Ph.D. and B.Sc. in Biochemistry, both from the University of Leeds.